Demographic data of solid tumor patients undergoing systemic cytotoxic chemotherapy and using prophylactic entecavir or lamivudine.

<p>^<i>a</i>Entecavir group included 6 head and neck cancers, 4 gynecologic cancers, and 7 genitourinary cancers. Lamivudine group included 31 head and neck cancers, 15 gynecologic cancers, and 11 genitourinary cancers.</p><p>^<i>b</i>SCC: systemic cytotoxic chemotherapy</p><p>^<i>c</i>ALT: alanine aminotransferase.</p><p>^<i>d</i>INR: international normalized ratio.</p><p>Demographic data of solid tumor patients undergoing systemic cytotoxic chemotherapy and using prophylactic entecavir or lamivudine.</p

Hepatitis B reactivation during systemic cytotoxic chemotherapy in solid tumor patients with a baseline HBV DNA level equal to or more than 2000 IU/mL and using prophylactic entecavir and lamivudine.

<p>Hepatitis B reactivation during systemic cytotoxic chemotherapy in solid tumor patients with a baseline HBV DNA level equal to or more than 2000 IU/mL and using prophylactic entecavir and lamivudine.</p

Baseline characteristics of the patients.

a<p>Data presented as mean +/− standard deviation.</p><p>AFP: alpha-fetoprotein, CLIP: Cancer of the Liver Italian Program, BCLC: Barcelona-Clinic Liver Cancer.</p

Comparison of the overall survival rate between the HAIC and symptomatic treatment group.

<p>The HAIC group had significantly better survival than the symptomatic treatment group (P<0.001).</p

Adverse events of patients who received HAIC according to NCI-CTC AE grading.

<p>Adverse events of patients who received HAIC according to NCI-CTC AE grading.</p